Furthermore, a significant increase in the median model for end-stage liver disease-sodium (MELD-Na) scores was observed with the approval of dual (9 [6–14] vs 10 [8–15], P < .013) and triple (9 [6–14] vs 12.5 [8–17], P < .003) CFTR modulators (Table 2). The gene discussed is CFTR; the disease is End Stage Liver Disease.